430 related articles for article (PubMed ID: 28528007)
1. Luteolin as a potential preventive and therapeutic candidate for Alzheimer's disease.
Kwon Y
Exp Gerontol; 2017 Sep; 95():39-43. PubMed ID: 28528007
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Pathological Benefit of Twendee X in Alzheimer's Disease Transgenic Mice with Chronic Cerebral Hypoperfusion.
Liu X; Yamashita T; Shang J; Shi X; Morihara R; Huang Y; Sato K; Takemoto M; Hishikawa N; Ohta Y; Abe K
J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1993-2002. PubMed ID: 31029568
[TBL] [Abstract][Full Text] [Related]
3. Protection against Alzheimer's disease by luteolin: Role of brain glucose regulation, anti-inflammatory activity, and the gut microbiota-liver-brain axis.
Daily JW; Kang S; Park S
Biofactors; 2021 Mar; 47(2):218-231. PubMed ID: 33347668
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammation in Alzheimer's disease and beneficial action of luteolin.
Delgado A; Cholevas C; Theoharides TC
Biofactors; 2021 Mar; 47(2):207-217. PubMed ID: 33615581
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of luteolin against cognitive impairment induced by infusion of Aβ peptide in rats.
Yu TX; Zhang P; Guan Y; Wang M; Zhen MQ
Int J Clin Exp Pathol; 2015; 8(6):6740-7. PubMed ID: 26261557
[TBL] [Abstract][Full Text] [Related]
6. Prospects of Marine Sterols against Pathobiology of Alzheimer's Disease: Pharmacological Insights and Technological Advances.
Rahman MA; Dash R; Sohag AAM; Alam M; Rhim H; Ha H; Moon IS; Uddin MJ; Hannan MA
Mar Drugs; 2021 Mar; 19(3):. PubMed ID: 33804766
[TBL] [Abstract][Full Text] [Related]
7. Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.
Shadfar S; Hwang CJ; Lim MS; Choi DY; Hong JT
Arch Pharm Res; 2015 Dec; 38(12):2106-19. PubMed ID: 26289122
[TBL] [Abstract][Full Text] [Related]
8. Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimer's Disease: a Review of Current Evidence.
Mohammadzadeh Honarvar N; Saedisomeolia A; Abdolahi M; Shayeganrad A; Taheri Sangsari G; Hassanzadeh Rad B; Muench G
J Mol Neurosci; 2017 Mar; 61(3):289-304. PubMed ID: 27864661
[TBL] [Abstract][Full Text] [Related]
9. Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotropic factor, neuroinflammation and oxido-nitrosative stress.
Ali MR; Abo-Youssef AM; Messiha BA; Khattab MM
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):637-56. PubMed ID: 27026404
[TBL] [Abstract][Full Text] [Related]
10. The effects of C-glycosylation of luteolin on its antioxidant, anti-Alzheimer's disease, anti-diabetic, and anti-inflammatory activities.
Choi JS; Islam MN; Ali MY; Kim YM; Park HJ; Sohn HS; Jung HA
Arch Pharm Res; 2014 Oct; 37(10):1354-63. PubMed ID: 24988985
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties.
Siddiqui A; Shah Z; Jahan RN; Othman I; Kumari Y
Biomed Pharmacother; 2021 Dec; 144():112250. PubMed ID: 34607104
[TBL] [Abstract][Full Text] [Related]
12. The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.
Pimentel LS; Allard S; Do Carmo S; Weinreb O; Danik M; Hanzel CE; Youdim MB; Cuello AC
J Alzheimers Dis; 2015; 47(2):373-83. PubMed ID: 26401560
[TBL] [Abstract][Full Text] [Related]
13. Protective role of luteolin against cognitive dysfunction induced by chronic cerebral hypoperfusion in rats.
Fu X; Zhang J; Guo L; Xu Y; Sun L; Wang S; Feng Y; Gou L; Zhang L; Liu Y
Pharmacol Biochem Behav; 2014 Nov; 126():122-30. PubMed ID: 25220684
[TBL] [Abstract][Full Text] [Related]
14. Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin.
Facchinetti R; Valenza M; Bronzuoli MR; Menegoni G; Ratano P; Steardo L; Campolongo P; Scuderi C
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471239
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's Disease and Functional Foods: An Insight on Neuroprotective Effect of its Combination.
Hasnieza Mohd Rosli N; Mastura Yahya H; Shahar S; Wahida Ibrahim F; Fadilah Rajab N
Pak J Biol Sci; 2020 Jan; 23(5):575-589. PubMed ID: 32363814
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.
Karl T; Garner B; Cheng D
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):142-160. PubMed ID: 27471947
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and Pharmaco-therapeutic Potential of Luteolin in Overcoming Alzheimer's Disease.
Ali F; Siddique YH
CNS Neurol Disord Drug Targets; 2019; 18(5):352-365. PubMed ID: 30892166
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and Alzheimer's disease.
Lee YJ; Han SB; Nam SY; Oh KW; Hong JT
Arch Pharm Res; 2010 Oct; 33(10):1539-56. PubMed ID: 21052932
[TBL] [Abstract][Full Text] [Related]
19. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease.
Agostinho P; Cunha RA; Oliveira C
Curr Pharm Des; 2010; 16(25):2766-78. PubMed ID: 20698820
[TBL] [Abstract][Full Text] [Related]
20. Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential.
Kabir MT; Uddin MS; Jeandet P; Emran TB; Mitra S; Albadrani GM; Sayed AA; Abdel-Daim MM; Simal-Gandara J
Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33925063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
